Literature DB >> 29072564

The histopathological effects of intracavernosal mitomycin-C injection in a rat Peyronie's disease model.

Engin Kaya1, Yusuf Kibar2, Sercan Yilmaz1, Ayhan Ozcan3, Burak Kopru4, Turgay Ebiloglu1, Hasan Cem Irkilata1.   

Abstract

INTRODUCTION: We aimed to evaluate whether or not mitomycin-C (MMC) has an antifibrotic effect on transforming growth factor-beta (TGF-β)-induced Peyronie's disease (PD) in a rat model.
METHODS: Eighteen 12-week-old male Sprague-Dawley rats were divided into three groups: Group 1=TGF-β1 (n=7); Group 2=TGF-β1+MMC (n=7); and Group 3=Sham group (0.25 ml bovine serum albumin injected) (n=4). All groups were sacrificed on the sixth week of the procedure and their penises were excised. All penis specimens were evaluated semi-quantitatively and quantitatively with histochemical, immunohistochemistry, and image analysis.
RESULTS: Both Group 1 and Group 2 had significantly higher fibrosis scores and lower elastic fibers in both outer surface of tunica albuginea (TA) and subsinusoidal area compared with Group 3. When compared with Group 1, the amount of collagen was significantly decreased in Group 2. Intracavernosal MMC injection (Group 2) ended up with lower elastic fibers when compared with Group 1. According to the quantitative analyses, when compared with Groups 1 and 3, lower dorsal, ventral, and trabecular thickening values were seen in Group 2. These parameters were only statistically significant when compared with Group 1, suggesting the antifibrotic effect of TGF-β1-induced fibrosis. Both Groups 1 and 2 showed lower decorin staining levels in subsinusoidal areas of tunica albuginea (SATA) and subsinusoidal areas of trabecular wall (SATW) when compared with Group 3. The statistically significant difference was only detected between Group 1 and Group 3.
CONCLUSIONS: Our study demonstrates the antifibrotic effects of MMC on PD. Further clinical studies are necessary to make inferences regarding its clinical use.

Entities:  

Year:  2017        PMID: 29072564      PMCID: PMC5698024          DOI: 10.5489/cuaj.4489

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  24 in total

Review 1.  Peyronie's disease: etiology, epidemiology and medical treatment.

Authors:  Jason M Greenfield; Laurence A Levine
Journal:  Urol Clin North Am       Date:  2005-11       Impact factor: 2.241

2.  Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression.

Authors:  A I El-Sakka; H M Hassoba; R J Pillarisetty; R Dahiya; T F Lue
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

Review 3.  [Pathophysiology and management of Peyronie's disease in adult patients: an update].

Authors:  O Alenda; S Beley; K Ferhi; F Cour; E Chartier-Kastler; A Haertig; F Richard; M Rouprêt
Journal:  Prog Urol       Date:  2009-07-03       Impact factor: 0.915

4.  Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease.

Authors:  Martin Gelbard; Larry I Lipshultz; James Tursi; Ted Smith; Greg Kaufman; Laurence A Levine
Journal:  J Urol       Date:  2012-04-13       Impact factor: 7.450

5.  The effect of mitomycin C in reducing epidural fibrosis after lumbar laminectomy in rats.

Authors:  Jin-Yul Lee; Werner Stenzel; Peter Impekoven; Martin Theisohn; Hartmut Stützer; Mario Löhr; Thomas Reithmeier; Ralf-Ingo Ernestus; Heinrich Ebel; Norfrid Klug
Journal:  J Neurosurg Spine       Date:  2006-07

6.  Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behavior.

Authors:  N L Occleston; J T Daniels; R W Tarnuzzer; K K Sethi; R A Alexander; S S Bhattacharya; G S Schultz; P T Khaw
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-09       Impact factor: 4.799

7.  Decorin as a new treatment alternative in Peyronie's disease: preliminary results in the rat model.

Authors:  T Akman; A Tefekli; A Armagan; I Kiliçaslan; B Özerman; A Tepeler; A Kadioğlu
Journal:  Andrologia       Date:  2012-06-06       Impact factor: 2.775

8.  Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease.

Authors:  H H Davila; M G Ferrini; J Rajfer; N F Gonzalez-Cadavid
Journal:  BJU Int       Date:  2003-06       Impact factor: 5.588

9.  Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease.

Authors:  Landon W Trost; Erhan Ates; Mary Powers; Suresh Sikka; Wayne J G Hellstrom
Journal:  J Urol       Date:  2013-05-18       Impact factor: 7.450

10.  Lingual mucosal graft in treatment of Peyronie disease.

Authors:  Emad A Salem; Ehab H Elkady; Ahmed Sakr; Aref M Maarouf; Lotfy Bendary; Salem Khalil; Ashraf Shahin; Hussein Kamel
Journal:  Urology       Date:  2014-10-03       Impact factor: 2.649

View more
  1 in total

1.  Treatment with Hyaluronic Acid and Collagen-Polyvinylpyrrolidone Improves Extracellular Matrix Assembly for Scarring after Tracheal Resection.

Authors:  J Raúl Olmos-Zuñiga; Matilde Baltazares-Lipp; Claudia Hernández-Jiménez; Rogelio Jasso-Victoria; Miguel Gaxiola-Gaxiola; Mariana Silva-Martínez; Marco Antonio Iñiguez-García; A Ivan González-González; Juan Carlos Vázquez-Minero; Antonia Luna-Flores; Norma Solis-Alanis; Mario Enrique Baltazares-Lipp
Journal:  Biomed Res Int       Date:  2020-08-27       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.